Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

All NewsMay 11, 2026

Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT